N/A N=40 Recovery of Bladder and Sexual Function After Spinal Cord Injury
Spinal Cord Injuries
Primary: Bladder Storage — 278.5; 447.75; 580.5; 313.0 mLH2O
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=214 Cystoinflation to Prevent Bladder Injury in Obstetrics and Gynaecology Surgery
Bladder Injury · Complications; Cesarean Section · Adhesions Pelvic
Primary: Bladder Injury Rate — 3; 22 Participants — p=<.0001
N/A N=26 Bladder ARFI (Acoustic Radiation Force Impulse) Study
Bladder Fibrosis
Primary: Shear Wave Velocity, VTQ — 1.95 meters per second
N/A N=45 BULLET: Bladder Ultrasound Limits Length (of Time), Expedites Treatment
Point-of-Care Bladder Ultrasound · Urethral Catheter
Primary: Time to Successful Completion of Pelvic Ultrasound — 103.95; 92.82 minutes
N/A N=84 Treatment for Acute Postoperative Voiding Dysfunction
Urinary Retention
Primary: Persistent Retention — 29; 21 participants
Phase 1 N=3 Two Devices for Reflex Voiding Following Spinal Cord Injury
Spinal Cord Injury · Urinary Incontinence
Primary: Number of Participants With a Change in Bladder Pressure — 0 participants
N/A N=174 Recovery Support for Bladder Cancer Patients and Caregivers
Bladder Cancer · Patient Engagement · Patient Empowerment
Primary: Quality of Life Patient: The Functional Assessment of Cancer Therapy-Bladder Cancer-Cystectomy — 117.59; 118.70 Quality of Life Score — p=0.772
N/A N=47 Navigation of the Pelvic Floor in Bladder Exstrophy Using Pre-operative MRI
Bladder Exstrophy
Primary: Success or Failure of Exstrophy Closure — 44; 0 exstrophy closures
N/A N=44 Effects of Ketamine on Human Bladders and Its Possible Mechanisms
Cystitis
Primary: Substance Abuse Situation Record — 2 years
N/A N=19 The Effects Upon the Bladder of Transcutaneous Tibial Nerve Stimulation in Acute Traumatic Spinal Cord Injury
Spinal Cord Injury · Neurogenic Bladder
Primary: Number of Participants With Infection — 4; 3 Participants
Phase 1 N=13 Colonizing Neurogenic Bladders With Benign Flora
Spinal Cord Injury · Urinary Tract Infection
Primary: Bladder Colonization — 62 percentage of participants
Phase 2 N=37 Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients
Spinal Cord Injuries
Primary: Net Change of the Urinary Distress Inventory (UDI-6) — 10.4; 7.43 units on a scale
N/A N=11 Brain Targets in Patients With Bladder Emptying Difficulties
Neurogenic Bladder · Multiple Sclerosis · Voiding Dysfunction
Primary: Changes in Brain Activity After Treatment Measured Using Functional MRI — 2.759234; 3.423569; 3.000987; 3.094914 BOLD fMRI T-Value — p=<0.05
N/A N=491 Urinary Retention After Laparoscopic Inguinal Hernia Repair: Comparing the Use of the Intraoperative Urinary Catheter
Inguinal Hernia
Primary: Number of Participants With Post Operative Urinary Retention — 23; 21 Participants
Phase 4 N=120 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
Multiple Sclerosis · Urinary Bladder Diseases
Primary: Change From Baseline in the King's Health Questionnaire (KHQ) Domain Scores — 39.7; 2.5; 60.7; 1.2 Scores on a Scale
Phase 2 N=43 BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
Muscle Invasive Bladder Cancer
Primary: Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging…
Phase 3 N=23 Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury
Urinary Tract Infections · Spinal Cord Injuries · Spinal Cord Diseases
Primary: Number of Urinary Tract Infections (UTI) Over Time — 0.53; 0.09 UTI events per person months. — p=<0.0001
Phase 3 N=82 The Bladder Instillation Comparison Study
Urinary Bladder Neoplasms
Primary: Number of Participants Without Grade ≥ 3 Adverse Event, Graded According to NCI CTCAE Version 4.03 — 15; 14; 20 Participants
N/A N=30 Transcutaneous Peripheral Neuromodulation for Neurogenic Bladder
Urinary Bladder, Neurogenic
Primary: Patient Perception of Bladder Condition Questionnaire — 3; 3 units on a scale
Phase 3 N=133 Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
Bladder Cancer
Primary: Complete Response Rate at 3 Months — 39 percentage of participants
Phase 2 N=15 Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
Bladder Cancer
Primary: Evaluate the Efficacy for Treatment of Low/Intermediate- Risk Bladder Tumors, Assessing for the Clinical Response of the Marker Lesion — 13 Participants
Phase 2 N=2 Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer
Urothelial Carcinoma of the Bladder
Primary: Number of Participants With Adverse Events — 2 Participants
Phase 2 N=43 Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
Urinary Tract Urothelial Carcinoma
Primary: Number of Participants With Complete Response at 3 Months — 26 Participants
N/A N=70 Surgical Study Comparing 2 Procedures for the Treatment of a Dropped Bladder
Prolapse
Primary: Change in the Stage of Prolapse of the Anterior Vaginal Wall Before and One Year After Surgery
Phase 4 N=20 Botox as a Treatment for Interstitial Cystitis in Women
Painful Bladder Syndrome · Interstitial Cystitis
Primary: Chronic Prostatitis Symptom Index (CPSI-F) — 29.6; 35.2 Total CPSI-F
Phase 2 N=9 Botulin-A Toxin Instillations and Overactive Bladder
Overactive Bladder · Detrusor Instability · Detrusor Hyperreflexia
Primary: Median Number of Incontinent Episodes During 24 Hours — 4; 2; 4 number of incontinent episodes — p=0.004
Phase 2 N=37 Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
Bladder Cancer
Primary: Percentage of Participants Free From Radical Cystectomy at 3 Years — 88.2 percentage of participants
Phase 3 N=416 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
Overactive Bladder
Primary: Change From Baseline in Number of Weekly Episodes of Urinary Incontinence — 31.1; 32.3; 28.3; -22.7 Number of Weekly Episodes
Phase 3 N=275 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
Overactive Bladder
Primary: Change From Baseline in Number of Weekly Episodes of Urinary Incontinence — 31.2; 32.5; 36.7; -19.4 Number of Weekly Episodes
N/A N=41 B3 Buddy for Securing Urinary Drainage Bag to Patient While Walking
Urinary System Disorder
Primary: Acceptability of Device — 100 percentage of participants